Blueprint
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending 20 February 2017
 
GlaxoSmithKline plc
(Name of registrant)

 
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

 
 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

 
 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

 
 
 
Yes      No x
 
 
GlaxoSmithKline plc (the 'Company')
 
 
 
GlaxoSmithKline plc
 
(the Company)
 
GlaxoSmithKline plc (the 'Company')
 
Shares withheld or sold to meet tax liabilities
Following the vesting of awards granted in 2014 under the GlaxoSmithKline 2009 Performance Share Plan on 16 February 2017 and as notified on 17 February 2017, the notifications that follow reflect changes in the interests of Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them ('PCA") in Ordinary Shares and in American Depositary Shares (ADSs) of the Company arising from the sale or withholding of Ordinary Shares or ADSs to meet tax liabilities. This notification also includes the sale further to the vesting of awards granted in 2012 to Sir Andrew Witty which were subject to an additional holding period.   
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Sir Andrew Witty
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2012 and 2014 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.2437
9,057
£16.2437
166
£16.2437
55,441
d)
Aggregated information
 
Aggregated volume Price
 
    64,664     £16.2437
 
e)
Date of the transaction
2017-02-16
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
CEO Designate
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.2437
19,218
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
e)
Date of the transaction
2017-02-16
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R G Connor
b)
Position/status
President, Global Manufacturing and Supply
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.2437
14,957
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
e)
Date of the transaction
2017-02-16
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S Dingemans
b)
Position/status
Chief Financial Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.2437
32,529
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
e)
Date of the transaction
2017-02-16
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
GlaxoSmithKline plc American Depositary Shares ('ADSs')
 
ISIN: US37733W1053
b)
Nature of the transaction
The withholding of ADSs to meet tax liabilities further to the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$40.57
1,255
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
e)
Date of the transaction
2017-02-16
f)
Place of the transaction
 
n/a
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S A Hussain
b)
Position/status
President, Global Pharmaceuticals
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.2437
27,371
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
e)
Date of the transaction
2017-02-16
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr B McNamara
b)
Position/status
CEO, Consumer Healthcare
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
GlaxoSmithKline plc American Depositary Shares ('ADSs')
 
ISIN: US37733W1053
b)
Nature of the transaction
The withholding of ADSs to meet tax liabilities further to the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$40.57
10,082
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
e)
Date of the transaction
2017-02-16
f)
Place of the transaction
 
n/a
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D S Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.2437
10,738
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
e)
Date of the transaction
2017-02-16
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms C Thomas
b)
Position/status
SVP, Human Resources
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.2437
15,320
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
e)
Date of the transaction
2017-02-16
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P C Thomson
b)
Position/status
SVP, Communications & Government Affairs
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.2437
7,307
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
e)
Date of the transaction
2017-02-16
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D E Troy
b)
Position/status
SVP & General Counsel
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
GlaxoSmithKline plc American Depositary Shares ('ADSs')
 
ISIN: US37733W1053 
b)
Nature of the transaction
The withholding of ADSs to meet tax liabilities further to the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$40.57
13,035
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
e)
Date of the transaction
2017-02-16
f)
Place of the transaction
 
n/a
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr P J T Vallance
b)
Position/status
President, R&D
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.2437
32,996
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
e)
Date of the transaction
2017-02-16
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mrs V A Whyte
b)
Position/status
Company Secretary
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.2437
2,197
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
e)
Date of the transaction
2017-02-16
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr K Slaoui
b)
Position/status
PCA of Dr M M Slaoui (Chairman, Global Vaccines)
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
GlaxoSmithKline plc American Depositary Shares ('ADSs')
 
ISIN: US37733W1053
b)
Nature of the transaction
The withholding of ADSs to meet tax liabilities further to the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$40.57
249
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
e)
Date of the transaction
2017-02-16
f)
Place of the transaction
 
n/a
               
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: February 20, 2017 
 
 
 
 
By: VICTORIA WHYTE--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc